Pluri

Executive Summary

Pluri Biotech Ltd. is an Israeli company specializing in a patented three-dimensional cell expansion platform that mass-produces placental-derived mesenchymal-like cells (PLX). The technology enables scalable, automated, and cost-effective manufacturing of high-quality cells for therapeutic and industrial use. Pluri's primary applications include regenerative medicine, orthopedics, and cultivated food. The company is currently in Phase 3 clinical trials, targeting unmet medical needs in areas such as severe limb ischemia and orthopedic conditions. With a strong intellectual property portfolio and a versatile platform, Pluri is positioned to disrupt cell therapy manufacturing by reducing costs and improving consistency. The company's expansion into cultivated food represents a novel diversification that addresses the growing demand for sustainable protein sources. Despite being private, Pluri has demonstrated technological validation through partnerships and advancing trials, making it a notable player in the regenerative medicine and cellular agriculture spaces.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 clinical trial results for PLX-PAD in critical limb ischemia65% success
• H2 2026Partnership or licensing deal for cultivated food technology50% success
• Q3 2026Regulatory milestone for orthopedic indication (e.g., FDA or EMA acceptance)55% success